Evaxion Biotech CEO Christian Kanstrup joined Steve Darling from Proactive to announce the launch of an enhanced version of the company’s clinically validated AI-Immunolog platform, featuring an updated EDEN AI prediction model. The upgraded model enhances the prediction of toxin antigens, which is critical for the development of next-generation bacterial vaccines.
Kanstrup explained that the new EDEN model significantly improves the speed and accuracy of predicting bacterial toxins, enabling Evaxion to rapidly identify the key toxin targets for vaccine development. This advancement represents a major step forward in the company’s mission to address unmet medical needs in infectious diseases.
Evaxion’s AI-Immunology platform leverages advanced AI and machine learning technologies to design novel vaccine candidates for cancer and infectious diseases. The platform’s AI prediction models are adaptable to other therapeutic areas, offering delivery modality flexibility and unmatched predictive capabilities.
Remarkably, the platform can deliver a new target within just 24 hours, a process that traditionally takes years. The platform’s predictions are robustly validated, with strong correlations between the AI-generated prediction scores and clinical outcomes, underscoring the potential impact of this technology in vaccine development.
Kanstrup also provided an update on the company’s cancer pipeline, particularly the personalized cancer vaccine *EVX-01*, which is in phase two trials for metastatic melanoma. Early clinical data revealed a promising 69% overall response rate, with tumor size reductions in 15 out of 16 patients.
#proactiveinvestors #evaxionniotecha/s #AIvaccine #CancerVaccine #Eden5 #BiotechInnovation #PharmaPartnerships #InfectiousDiseases #ClinicalTrials #PersonalizedMedicine #ProactiveNews #VaccineDevelopment
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews